For example Kynamro, an antisense inhibitor of apolipoprotein B [32], the principal apoprotein present on all atherogenic lipids [38], was approved by the FDA in January 2013 for use as an adjunct to first-line lipid-lowering therapies in homozygous familial hypercholesterolemia [39–41]. This evidence concerns the gene APOB and familial hypercholesterolemia.